scholarly journals The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Eunyoung Heo ◽  
Eunyoung Kim ◽  
Eun Jin Jang ◽  
Chang-Hoon Lee
Keyword(s):  
Diabetes Mellitus ◽  
Cumulative Dose ◽  
Regression Models ◽  
Proportional Hazard ◽  
Newly Diagnosed ◽  
Hazard Regression ◽  
Cox Proportional Hazard ◽  
Type 2 Dm ◽  
Cox Proportional Hazard Regression

Abstract Background Diabetes mellitus (DM) is a well-known risk factor for tuberculosis (TB). Metformin, which is an essential anti-diabetic drug, has been shown to exhibit anti-TB effects in patients with DM. Its effect on preventing the development of TB among patients who are newly diagnosed with DM remains unclear. Methods This was a retrospective cohort study using the claims database of the Korean Health Insurance Review and Assessment Service. The study population included patients who were newly diagnosed with type 2 DM and who were treated with anti-diabetic drugs between 1 January 2003 and 31 March 2011. A patient was defined as a metformin user if he/she had taken metformin for more than 28 days within 6 months since cohort entry, and as a metformin non-user if he/she had never been treated with metformin. The development of TB within 2 years after the index date was compared by Cox proportional hazard regression models between metformin users and 1:1 propensity score (PS)-matched non-users. Results Among 76,973 patients who were newly diagnosed with type 2 DM, 13,396 were classified as metformin users, 52,736 were classified as metformin non-users, and 10,841 were excluded from the final analysis. PS-matched Cox proportional hazard regression models revealed that metformin use was not associated overall with the prevention of TB development (HR 1.17; 95% CI 0.75–1.83; P = 0.482). There was a trend, however, towards a reduction in the development of TB among patients taking a higher cumulative dose of metformin. Patients who were in the highest quartile (Q4) of cumulative metformin dose had only a 10% risk of developing TB compared to metformin non-users. In contrast, during the early phases of metformin treatment, patients in the second quartile (Q2) of cumulative metformin use had a higher risk of developing TB than patients in the first quartile (Q1). Conclusions Only the highest cumulative doses of metformin were protective against the development of TB among patients who were newly diagnosed with type 2 DM; lower cumulative doses of metformin did not appear to reduce the incidence of active TB infection.

scholarly journals The Cumulative Dose-Dependent Effects of Metformin on the Development of Tuberculosis in Patients Newly Diagnosed with Type 2 Diabetes Mellitus

2021 ◽  
Author(s):  
Eunyoung Heo ◽  
Eunyoung Kim ◽  
Eun Jin Jang ◽  
Chang-Hoon Lee
Keyword(s):  
Diabetes Mellitus ◽  
Cumulative Dose ◽  
Primary Outcome ◽  
Newly Diagnosed ◽  
Cohort Entry ◽  
Type 2 Dm ◽  
Initial Cohort ◽  
Study Population ◽  
Dose Dependent

Abstract Background: Diabetes mellitus (DM) is a well-known risk factor for tuberculosis (TB). Metformin, which is an essential anti-diabetic drug, has been shown to exhibit anti-TB effects in patients with DM. Its effect on preventing the development of TB among patients who are newly diagnosed with DM remains unclear. We evaluated the protective effect of metformin on the development of TB among newly diagnosed patients with type 2 DM.Methods: This was a retrospective cohort study using the claims database. The study population included newly diagnosed type 2 DM patients between January 2003 and March 2011. A metformin user was defined if a patient had taken metformin for more than 28 days within the first 6 months after the initial cohort entry. Primary outcome was the development of TB within 2 years after the index date. Results: Metformin use was not associated with the prevention of TB development (Metformin user: 44/12,916 (0.34%) vs. Metformin non-user: 40/12,916(0.31%); HR, 1.17; 95% CI, 0.75-1.83; P = 0.482). There was, however, a reduction in the development of TB among patients taking a higher cumulative dose of metformin. Patients in the highest quartile of cumulative metformin dose had only a 10% risk of developing TB compared to metformin non-users. In contrast, patients in the second quartile had a higher risk of developing TB than patients in the first quartile. Conclusions: The highest cumulative doses of metformin were protective against the development of TB among newly diagnosed type 2 DM patients.

scholarly journals AB0292 EFFICACY AND SAFETY OF TWO BIOSIMILAR ETANERCEPT AFTER THE SWITCH FROM THEIR CORRESPONDING ORIGINATOR IN THE TREATMENT OF PATIENTS WITH AUTOIMMUNE ARTHRITIS; A RETROSPECTIVE ANALYSIS IN A REAL LIFE SETTING

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1445.1-1445
Author(s):  
F. Girelli ◽  
A. Ariani ◽  
M. Bruschi ◽  
A. Becciolini ◽  
L. Gardelli ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Disease Duration ◽  
Retention Rate ◽  
Real Life ◽  
Autoimmune Arthritis ◽  
Proportional Hazard ◽  
Hazard Regression ◽  
Cox Proportional Hazard ◽  
Real Life Setting ◽  
Cox Proportional Hazard Regression

Background:The available biosimilars of etanercept are as effective and well tolerated as their bio originator molecule in the naive treatment of chronic autoimmune arthritis. More data about the switching from the bio originator are needed.Objectives:To compare the clinical outcomes of the treatment with etanercept biosimilars (SB4 and GP2015) naïve and after the switch from their corresponding originator in patients affected by autoimmune arthritis in a real life settingMethods:We retrospectively analyzed the baseline characteristics and the retention rate in a cohort of patients who received at least a course of etanercept (originator or biosimilar) in our Rheumatology Units from January 2000 to January 2020. We stratified the study population according to biosimilar use. Descriptive data are presented by medians (interquartile range [IQR]) for continuous data or as numbers (percentages) for categorical data. Drug survival distribution curves were computed by the Kaplan-Meier method and compared by a stratified log-rank test. A Cox proportional hazards regression analysis stratified by indication, drug, age, disease duration, sex, treatment line, biosimilar use and prescription year was performed. P values≤0.05 were considered statistically significant.Results:477 patients (65% female, median age 56 [46-75] years, median disease duration 97 [40.25-178.75] months) treated with etanercept were included in the analysis. 257 (53.9%) were affect by rheumatoid arthritis, 139 (29.1%) by psoriatic arthritis, and 81 (17%) by axial spondylarthritis. 298 (62.5%) were treated with etanercept originator, 97 (20.3%) with SB4, and 82 (17.2%) with GP2015. Among the biosimilars 90/179 (50.3%) patients were naïve to etanercept treatment. Among the 89 switchers we observed 8 treatment discontinuations: one due to surgical infection complication, three due to disease flare, two due to subjective worsening and one due to remission. The overall 6- and 12-month retentions rate were 92.8% and 80.2%. The 6- and 12-month retention rate for etanercept, SB4 and GP2015 were 92.7%, 93.4% and 90.2%, and 82%, 74.5% and 88.1% respectively, without significant differences among the three groups (p=0.374). Patients switching from originator to biosimilars showed and overall higher treatment survival when compared to naive (12-month retention rate 81.2% vs 70.8%, p=0.036). The Cox proportional hazard regression analysis highlighted that the only predictor significantly associated with an overall higher risk of treatment discontinuation was the year of prescription (HR 1.08, 95% CI 1.04 to 1.13; p<0.0001).Conclusion:In our retrospective study etanercept originator and its biosimilars (SB4 and GP2015) showed the same effectiveness. Patients switching from originator to biosimilar showed an significant higher retention rate when compared to naive. The only predictor of treatment discontinuation highlighted by the Cox proportional hazard regression analysis was the year of treatment prescription.Disclosure of Interests:Francesco Girelli: None declared, Alarico Ariani: None declared, Marco Bruschi: None declared, Andrea Becciolini Speakers bureau: Sanofi-Genzyme, UCB and AbbVie, Lucia Gardelli: None declared, Maurizio Nizzoli: None declared

Association between Preoperative Monocyte-to-Lymphocyte Ratio and Late Arteriovenous Fistula Dysfunction in Hemodialysis Patients: A Cohort Study

2021 ◽  
pp. 1-7
Author(s):  
Shouliang Hu ◽  
Dan Wang ◽  
Tean Ma ◽  
Fanli Yuan ◽  
Yong Zhang ◽  
...  
Keyword(s):  
Cohort Study ◽  
Arteriovenous Fistula ◽  
Vessel Diameter ◽  
Transluminal Angioplasty ◽  
Proportional Hazard ◽  
Clinical Value ◽  
Hazard Regression ◽  
Lymphocyte Ratio ◽  
Cox Proportional Hazard ◽  
Cox Proportional Hazard Regression

<b><i>Background:</i></b> Inflammation appears to be at the biological core of arteriovenous fistula (AVF) dysfunction, and the occurrence of AVF dysfunction is related to high death and disability in hemodialysis (HD) patients. Despite several studies on the correlations between AVF dysfunction and inflammatory indicators, how AVF dysfunction is related to the monocyte-to-lymphocyte ratio (MLR) is much unclear. We hypothesize that preoperative MLR is associated with AVF dysfunction in Chinese HD patients. <b><i>Methods:</i></b> In this single-center retrospective cohort study, totally 769 adult HD patients with a new AVF created between 2011 and 2019 were included. Association of preoperative MLR with AVF dysfunction (thrombosis or decrease of normal vessel diameter by &#x3e;50%, requiring either surgical revision or percutaneous transluminal angioplasty) was assessed by multivariable Cox proportional hazard regression. <b><i>Results:</i></b> The patients were aged 55.8 ± 12.2 years and were mostly males (55%). During the average 32-month follow-up (maximum 119 months), 223 (29.0%) patients had permanent vascular access dysfunction. In adjusted multivariable Cox proportional hazard regression analyses, the risk of AVF dysfunction was 4.32 times higher with 1 unit increase in MLR (hazard ratio [HR]: 5.32; 95% confidence interval [CI]: 3.1–9.11). Compared with patients with MLR &#x3c;0.28, HRs associated with an MLR of 0.28–0.41 and ≥0.41 are 1.54 (95% CI: 1.02–2.32) and 3.17 (2.18–4.62), respectively. <b><i>Conclusions:</i></b> A higher preoperative MLR is independently connected with a severer risk of AVF dysfunction in HD patients. Its clinical value should be determined in the future.

scholarly journals PERBANDINGAN MODEL REGRESI COX PROPORTIONAL HAZARD MENGGUNAKAN METODE BRESLOW DAN EFRON (Studi Kasus: Penderita Stroke di RSUD Tugurejo Kota Semarang)

2019 ◽  
Vol 8 (1) ◽  
pp. 93-105
Author(s):  
Eri Setiani ◽  
Sudarno Sudarno ◽  
Rukun Santoso
Keyword(s):  
Blood Pressure ◽  
Systolic Blood Pressure ◽  
Regression Model ◽  
Diastolic Blood Pressure ◽  
Proportional Hazard ◽  
Hazard Regression ◽  
Cox Proportional Hazard ◽  
History Of ◽  
Cox Proportional Hazard Regression ◽  
Sugar Levels

Cox proportional hazard regression is a regression model that is often used in survival analysis. Survival analysis is phrase used to describe analysis of data in the form of times from a well-defined time origin until occurrence of some particular even or end-point. In analysis survival sometimes ties are found, namely there are two or more individual that have together event. This study aims to apply Cox model on ties event using two methods, Breslow and Efron and determine factors that affect survival of stroke patients in Tugurejo Hospital Semarang. Dependent variable in this study is length of stay, then independent variables are gender, age, type of stroke, history of hypertension, systolic blood pressure, diastolic blood pressure, blood sugar levels, and BMI. The two methods give different result, Breslow has four significant variables there are type of stroke, history of hypertension, systolic blood pressure, and diastolic blood pressure, while Efron contains five significant variables such as type of stroke, history of hypertension, systolic blood pressure, diastolic blood pressure and blood sugar levels. From the smallest AIC criteria obtained the best Cox proportional hazard regression model is Efron method. Keywords: Stroke, Cox Proportional Hazard Regression model, Breslow method, Efron method.

scholarly journals Factors that influence the recovery of TB patients using Cox proportional hazard regression

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
ZURNILA MARLI KESUMA ◽  
HIZIR SOFYAN ◽  
LATIFAH RAHAYU ◽  
WARDATUL JANNAH
Keyword(s):  
Control Program ◽  
Proportional Hazard ◽  
Cure Rate ◽  
Hazard Regression ◽  
Cox Proportional Hazard ◽  
National Tuberculosis Control Program ◽  
Record Data ◽  
National Tuberculosis ◽  
The Government ◽  
Cox Proportional Hazard Regression

Tuberculosis (TB) is an infectious disease which is one of the biggest health problems in the world, including Indonesia. The government, through the National Tuberculosis Control program, has made various efforts to control tuberculosis. However, this problem was exacerbated by the dramatic increase in the incidence of tuberculosis. This study aimed to determine the Cox proportional hazard regression model and the factors that affect the cure rate of TB patients. We used medical record data for inpatient TB patients for the period July-December 2017 at dr. Zainoel Abidin Hospital. The results showed that with α = 0.1, the factors that influenced the recovery of TB patients were the type of cough, the symptoms of bloody cough and symptoms of sweating at night.  There were 33.93% of patients who did not work. This category included students, domestic helpers, and those who did not work until they suffered from tuberculosis and were treated at dr. Zainoel Abidin Hospital. The hazard ratio (failure ratio) showed that the tendency or cure rate for TB patients who did not experience cough symptoms was 70% greater than patients who experienced phlegm cough symptoms. The cure rate for TB patients who experienced coughing up blood symptoms was 53% greater than patients without these symptoms. The cure rate for TB patients who experienced  symptoms of sweating at night was 54% greater than patients who did not sweat at night.

scholarly journals Factors That Affect Time to Switch From Warfarin to a Direct Oral Anticoagulant After Change in the Reimbursement Criteria in Patients With Atrial Fibrillation

2019 ◽  
Vol 25 (1) ◽  
pp. 57-64
Author(s):  
Susin Park ◽  
Nam Kyung Je
Keyword(s):  
Atrial Fibrillation ◽  
Regression Analysis ◽  
Oral Anticoagulant ◽  
Proportional Hazard ◽  
Direct Oral Anticoagulant ◽  
Hazard Regression ◽  
Cox Proportional Hazard ◽  
History Of ◽  
Cox Proportional Hazard Regression ◽  
Prior Stroke

Background: Anticoagulation therapy is recommended for stroke prevention in high-risk patients with atrial fibrillation (AF). This study aimed to estimate the time to switch from warfarin to a direct oral anticoagulant (DOAC) and identify the factors associated with it. Methods: By using claims data, we studied 7111 warfarin-using patients with nonvalvular AF who were aged ≥65 years. The Kaplan-Meier analysis was performed to estimate the time to switch from warfarin to a DOAC, and Cox proportional hazard regression analysis was used to estimate the influencing factors. Results: Approximately one-third of the patients (2403, 33.8%) switched from warfarin to a DOAC during the study period. Female sex, aged between 75 and 79 years, having a Medical Aid or Patriots and Veterans Insurance, hypertension, and history of prior stroke, and transient ischemic attack or thromboembolism (prior stroke/TIA/TE) were associated with a significantly shorter time to switch. The odds of switching to a DOAC were increased by approximately 1.2-fold in the women and 1.4-fold in the patients with prior stroke/TIA/TE. Conclusions: Approximately one-third of the warfarin-using patients switched from warfarin to a DOAC within 6 months after the change in the DOAC reimbursement criteria. In the Cox proportional hazard regression analysis, the factors that affected anticoagulant switching from warfarin to a DOAC were female sex and history of prior stroke/TIA/TE.

scholarly journals The association between dietary glycemic and insulin indices with incidence of cardiovascular disease: Tehran lipid and glucose study

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Farshad Teymoori ◽  
Hossein Farhadnejad ◽  
Parvin Mirmiran ◽  
Milad Nazarzadeh ◽  
Fereidoun Azizi
Keyword(s):  
Cardiovascular Disease ◽  
Regression Models ◽  
Glycemic Load ◽  
Proportional Hazard ◽  
Cox Proportional Hazard ◽  
Daily Energy ◽  
Glycemic Indices ◽  
The Mean ◽  
Cox Proportional Hazard Regression

Abstract Background The present study was conducted to investigate the association of dietary insulin index(II), insulin load(IL), glycemic index(GI), and glycemic load(GL) with the risk of cardiovascular disease(CVD). Methods This cohort study was conducted within the framework of the Tehran Lipid and Glucose Study on 2198 subjects, aged≥19 years old, who were followed-up for a median (IQR) 6.7 (6.1–7.1) years. Dietary GI, GL, II, and IL were calculated using a food frequency questionnaire at the baseline. Multivariate Cox proportional hazard regression models were used to estimate the risk of CVD across quartiles of dietary insulin and glycemic indices. Results Mean ± SD age of the subjects(44.9% men) was 38.3 ± 13.4 years. During a mean of 2406 ± 417 person-years of follow-up, 76(3.5%) new cases of the CVD were ascertained. The mean ± SD of II, IL, GI, and GL of participants were 51.7 ± 6.5, 235.8 ± 90.2, 61.9 ± 7.8, and 202.2 ± 78.1, respectively. After adjusting for the variables of age, sex, smoking, physical activity, daily energy intake, body mass index, diabetes, and hypertension, the hazard ratio (HR) of the highest quartile of dietary GL was 2.77(95%CI:1.00–7.69,P for trend:0.033) compared to the lowest one. Also, each one SD increase in the GL score was associated with a higher risk of CVD[(RR:1.46;CI:1.00–2.16),P-value = 0.047]. However, there was no significant association between the dietary GI, II, and IL and risk for CVD incidence. Conclusions Our results suggested that a high GL diet can increase the incidence of CVD, whereas high dietary II and IL were not associated with the risk of CVD among adults.

Sign in / Sign up

Export Citation Format

Share Document